Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 22, 2023

Outcomes After Fixed-Duration First-Line Ibrutinib Plus Venetoclax in Patients With CLL With High-Risk Features

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Clin. Cancer Res 2023 Jun 07;[EPub Ahead of Print], JN Allan, IW Flinn, T Siddiqi, P Ghia, CS Tam, TJ Kipps, PM Barr, A Elinder Camburn, A Tedeschi, XC Badoux, R Jacobs, BJ Kuss, L Trentin, C Zhou, A Szoke, C Abbazio, WG Wierda

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading